SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

88362L100

(CUSIP Number)

October 28, 2022

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 10 Pages

Item 1. Security and Issuer.

This Amendment No. 3 to Schedule 13D (this “Amendment”) is filed with respect to shares (the “Shares”) of the Common Stock, par value $0.001 per share (the “Common Stock”), of ThermoGenesis Holdings, Inc., a Delaware corporation (the “Issuer”). This Amendment is being filed jointly as a group pursuant to SEC Rule 13d-1(k) by Xiaochun “Chris” Xu (“Dr. Xu”) and Boyalife Group Inc., an Illinois corporation (“Boyalife Group”), (each of the foregoing being referred to individually as a “Reporting Person” and collectively as the “Reporting Persons”).

This Amendment is being filed to report a change in the respective ownership percentages of the Reporting Persons as a result of (1) the sale of 14,676,430 Shares pursuant to a registration statement on Form S-1, as amended (File No. 333-264242), which was declared effective on October 25, 2022 and which offering closed on October 28, 2022 (the “Offering”), and (2) the automatic adjustment in exercise price under the Amended Note (as defined below) to $0.14 per share on October 28, 2022, as a result of the Offering.

All historical share amounts disclosed herein have been adjusted to reflect the one-for-ten reverse stock split completed by the Issuer on June 4, 2019.

The address of Issuer’s principal executive offices is 2711 Citrus Road, Rancho Cordova, CA 95742.

Item 2. Identity and Background.

Below is information regarding each Reporting Person:

All of the capital stock of Boyalife Group is owned by Dr. Xu. Dr. Xu is the sole officer and director of Boyalife Group. Accordingly, Dr. Xu and Boyalife Group are deemed to have shared voting and investment power over securities held directly by Boyalife Group.

(d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is not subject to a judgement, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

The Reporting Persons may be deemed to be a member of a “group”, within the meaning of Section 13(d)(3) of the Act.

Item 3. Source and Amount of Funds or Other Consideration.

The information set forth under Item 6 is hereby incorporated by reference.

Item 4. Purpose of Transaction.

The information set forth under Item 6 is hereby incorporated by reference.

Item 5. Interest in Securities of the Issuer.

The ownership percentages set forth herein are based on 104,810,913 shares of the Issuer’s Common Stock, comprised of 45,997,792 Shares outstanding as of October 28, 2022, 58,703,871 Shares available upon conversion under the Amended Note, and 133,250 options held by Dr. Xu which vest within the next 60 days. “Beneficial Ownership” is defined pursuant to Rule 13d-3 of the Exchange Act, and generally means any person who directly or indirectly has or shares voting or investment power with respect to a security. A person shall be deemed to be the beneficial owner of a security if that person has the right to acquire beneficial ownership of the security within 60 days, including, but not limited to, any right to acquire the security through the exercise of any option or warrant or through the conversion of a security. Any securities not outstanding that are subject to options or warrants shall be deemed to be outstanding for the purpose of computing the percentage of outstanding securities of the class owned by that person, but shall not be deemed to be outstanding for the purpose of computing the percentage of the class owned by any other person.

(a)

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

On February 2, 2016, the Issuer entered into a Purchase Agreement (the “Purchase Agreement”) with Boyalife (Hong Kong) Limited, a Hong Kong company (“Boyalife HK”) and Boyalife Investment, Inc. (“Boyalife Investment”, and together with Boyalife HK, the “Investors”) pursuant to which the Issuer agreed to issue to issue to the Investors, in two closings, Shares, senior secured three-year convertible debentures, and a five-year warrant to purchase additional Shares, as further described below. The transactions contemplated by the Purchase Agreement are referred to as the “Boyalife Financing” for purposes hereof.

In the Boyalife Financing, which closed in two tranches on February 13 and February 16, 2016, (i) Boyalife HK purchased 73,529 Shares, for a purchase price of $34.00 per share (after giving effect to the Issuer’s 1-for-20 reverse stock split on March 4, 2016 and 1-for-10 reverse stock split on June 4, 2019), (ii) Boyalife Investment purchased Secured Convertible Debentures in the aggregate principal amount of $12.5 million initially convertible into 367,647 Shares (the “Debentures”), and (iii) Boyalife HK acquired a warrant to purchase an aggregate of 352,942 additional Shares at an exercise price of $80.00 per share (as adjusted to give effect to the March 2016 and June 2019 reverse stock splits) for a period of five years (the “Warrant”).

In connection with the Boyalife Financing, the Issuer also entered into a Nomination and Voting Agreement with the Investors (the “Nomination Agreement”). Pursuant to the terms of the Nomination Agreement, for so long as the Debentures remained outstanding and Boyalife HK owned of record or beneficially at least twenty percent (20%) of the issued and outstanding shares of the Issuer’s Common Stock, Boyalife HK had the right to designate one member to the Issuer’s Board of Directors. The Nomination Agreement further provided that, if upon and following the conversion of all of the principal and interest outstanding under the Debentures the Investors owned, in the aggregate, at least 50% of the issued and outstanding shares of the Issuer’s Common Stock, the Investors would have the right to designate up to a maximum of three members to the Issuer’s Board of Directors. The Nomination Agreement was amended and restated on April 16, 2018, as described below.

On August 22, 2016, the Issuer elected to convert all outstanding principal, together and interest accrued and otherwise payable (including the interest that would have accrued up to and including maturity under the Debentures) into an aggregate of 610,294 Shares.

On December 26, 2016, Boyalife Investment sold and transferred all 610,294 Shares held by it to Boyalife HK for a price per share equal to $25.20, resulting in Boyalife HK holding an aggregate of 683,824 Shares.

On March 6, 2017, the Issuer entered into a Credit Agreement (the “Credit Agreement”) with Boyalife Investment Fund II, Inc., which granted to the Issuer the right to borrow up to $5,000,000 any time prior to March 6, 2022 (the “Debt Facility”). On September 13, 2017, the Issuer and Boyalife Investment Fund II, Inc. entered into an amendment to the Credit Agreement increasing the maximum borrowing availability thereunder from $5.0 million to $10.0 million. The Debt Facility originally matured on March 6, 2022 (the “Maturity Date”). Interest accrues under the Debt Facility at a rate of 22% per annum, simple interest, with interest being payable annually.

On April 16, 2018, the Issuer entered into an amendment to the Debt Facility with Boyalife Asset Holding II, Inc., an Illinois corporation (“Boyalife Asset Holding II”), the successor by merger to Boyalife Investment Fund II, Inc. (“Lender”). In connection with the April 2018 amendment to the Debt Facility, the Issuer and Lender entered into a First Amended and Revolving Restated Credit Agreement (as amended to date, the “Amended Credit Agreement”) and a Second Amended and Restated Convertible Promissory Note (as amended to date, the “Amended Note”). The Amended Credit Agreement and Amended Note modified and amended the Debt Facility as follows:

In connection with Amended Credit Agreement, on April 16, 2018, the Issuer and Boyalife HK entered into a First Amended and Restated Nomination and Voting Agreement (the “Amended Nomination Agreement”), which amends and restates the above-described Nomination Agreement originally entered into on February 13, 2016. The Amended Nomination Agreement provides that Boyalife HK will have the right to designate a number of members of the Board of Directors of the Issuer that is in proportion to the “Boyalife Ownership Percentage”, which is Boyalife HK’s and its affiliates’ combined percentage ownership of outstanding common stock, treating as outstanding any shares of common stock underlying convertible securities that are immediately exercisable by Boyalife HK and its affiliates’ (including under the Amended Note) without any further payment. The Amended Nomination Agreement will terminate according to its terms when and if the Boyalife Ownership Percentage falls below 20%.

On May 7, 2018, the Issuer and Boyalife Asset Holding II entered into an Amendment No. 1 to the Amended Credit Agreement pursuant to which the Issuer granted to Boyalife Asset Holding II a security interest in shares held by the Issuer of ThermoGenesis Corp., a subsidiary of the Issuer, to secure repayment of the Amended Note.

On December 26, 2019, Boyalife HK sold to Boyalife Asset Holding II an aggregate of 683,824 Shares for an aggregate purchase price of $2,227,134 (or $3.33 per share) and warrants to purchase 352,942 shares of issuer common stock for an aggregate purchase price of $10.00. Accordingly, the transaction resulted in merely a change in the form of beneficial ownership of the subject Shares. The warrants expired on February 16, 2021.

On December 20, 2019, Boyalife Asset Holding II sold to a third party in a private transaction a participation interest in the Amended Note. Boyalife Asset Holding II sold to the third party a participation interest in the Convertible Note equal to $1,080,000 in face value of the Amended Note plus interest accruing thereon after December 20, 2019. Boyalife Asset Holding II retains sole voting and dispositive power over the Amended Note and is therefore deemed to own all Shares issuable upon any conversion of the Amended Note.

On March 4, 2022, the Issuer and Boyalife Asset Holding II entered into an Amendment No. 1 to the Amended Note, together with an Amendment No. 2 to the Amended Credit Agreement, to amend the maturity date thereunder to March 6, 2023 and to provide for payment on March 6, 2023 of accrued but unpaid interest through March 6, 2023 and to provide for payment of accrued interest thereafter on December 31 of each year.

On July 28, 2022, Dr. Xu, Boyalife Asset Holding II, and Boyalife Group consummated a transaction pursuant to which (i) Boyalife Asset Holding II sold to Boyalife Group all 12,281,091 Shares held by Boyalife Asset Holding II for a price of $0.21 per Share, and (ii) Boyalife Asset Holding II sold to Boyalife Group all of its interest under the Amended Note and Debt Facility for an aggregate price of $7,000,000, which was the outstanding principal amount of the Amended Note as of July 28, 2022. Boyalife Asset Holding II is wholly owned by Boyalife Group, and Boyalife Group is wholly owned by Dr. Xu. The purpose of this transaction was to effect an internal reorganization of the personal entities through which Dr. Xu beneficially holds his Shares and the Amended Note, and, accordingly, this transaction merely represented a change in the form of Dr. Xu’s beneficial ownership in the Issuer and did not result in any change in the amount of Dr. Xu’s beneficial ownership. As a result of this transaction, Boyalife Asset Holding II no longer holds any securities of the Issuer.

On October 28, 2022, the Issuer consummated the Offering which resulted in the change in the respective ownership percentages of the Reporting Persons reflected herein.

Item 7. Material to Be Filed as Exhibits.

*Previously filed

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 9, 2022